Cyclacel Pharmaceuticals (NASDAQ: CYCC)
Cyclacel Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cyclacel Pharmaceuticals Company Info
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
News & Analysis
Cyclacel Announces New Stock Issue
The pharmaceutical company hopes to reap gross proceeds of around $20 million from the offering.
5 of Last Week's Biggest Losers
These five stocks bucked last week's uptrend by taking a dive.
5 of Last Week's Biggest Winners
These five stocks soared over the past few days.
4 Biotechs' Dominant Moves
A closer look at today's big market movers
Why These 3 Biotech Stocks Are Winning
Gilead, Amarin, and Cyclacel are all up over 5%
ASCO Pops and Drops
Unfortunately, there were more of the latter.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.